Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAP2 | P11137 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9690283 | 0.85 | KDM4E (0.62) | KDM4EMAP2TDP1ALDH1A1NR4A2 | |
| SCHEMBL10596909 | 0.81 | KDM4E (0.49) | KDM4EMAP2TDP1ALDH1A1ATM | |
| SCHEMBL18824256 | 0.81 | MAP2 (0.62) | KDM4EMAP2TDP1ALDH1A1ATM | |
| SCHEMBL3624515 | 0.79 | NR4A2 (0.65) | KDM4EALDH1A1NR4A2KMT2AHSD17B10 | |
| SCHEMBL29050101 | 0.79 | MEN1 (0.61) | KDM4EMAP2TDP1ALDH1A1KMT2A | |
| SCHEMBL29025503 | 0.79 | MAP2 (0.47) | KDM4EMAP2TDP1ALDH1A1ATM | |
| SCHEMBL17669160 | 0.79 | PDGFRB (0.54) | KDM4EMAP2TDP1ALDH1A1KMT2A | |
| SCHEMBL1807094 | 0.79 | NR4A2 (0.69) | KDM4EALDH1A1NR4A2KMT2AHSD17B10 | |
| SCHEMBL721793 | 0.78 | MAP2 (0.58) | KDM4EMAP2TDP1ALDH1A1KMT2A | |
| SCHEMBL17680433 | 0.77 | MAP2 (0.45) | KDM4EMAP2TDP1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445529-B2 | Indole derivative having, carbamoyl group, ureido group and substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| CN-101583598-B | Novel indole derivative having inhibitory activity on i kappa b kinase | SANTEN PHARMACEUTICAL CO LTD | 2012-09-12 | — | — | CN | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| CN-101583598-A | Novel indole derivative having inhibitory activity on i kappa b kinase ss | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-18 | — | — | CN | disclosed |
| EP-1432715-B1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-7312224-B2 | Pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20040242595-A1 | Pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1432715-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003031447-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | IKBKB, CHUK, RELA | KDM4E 406/4885MAP2 2793/4885TDP1 3397/4885 |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | KDM4E 1670/4885MAP2 964/4885TDP1 1270/4885 |
| US-20040242595-A1 | Pyrimidine derivatives | TYMP, DPYD, TYMS | KDM4E 2620/4885MAP2 4770/4885TDP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.